Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to protect mothers and babies through unspecified health provisions.
The problem
The bill title suggests concerns about maternal and infant health outcomes, though specific issues are not detailed in available documentation.
The proposal
Without official summary or text, the specific legislative changes cannot be determined. Bill requires committee review to clarify proposed actions.
The impact
Likely affects pregnant women, mothers, and infants, but scope depends on final bill provisions currently under committee consideration.
If the bill addresses maternal mortality or pregnancy complications, it could improve health outcomes for pregnant women and new mothers. Many states have high maternal death rates, particularly among certain demographics.
The bill may establish safeguards or programs benefiting infants' health and development. Early intervention and health monitoring can reduce long-term health problems.
Maternal and infant health are areas with potential bipartisan support. Common ground on health protections may enable constructive legislation.
No official summary means legislators and public cannot evaluate the bill's actual content or costs. This makes informed debate and decision-making difficult.
Without bill details, costs to federal budget are unclear. New health programs may require significant taxpayer funding or affect other priorities.
Health legislation can affect insurance markets, healthcare provider practices, and family choices in unexpected ways. Full text review is necessary before passage.
Without clear specifications, execution by healthcare agencies could vary widely. This may create inconsistent protections across states or populations.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Other bills in this policy area
HR 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
HR 10858
CARE for Blood Cancer Act of 2026
HR 10874
Medicare Low Income Subsidy Equality Act of 2026
HR 10887
Protecting Consumer Access to Generic Drugs Act of 2026
Individual contributions, grouped by employer · FEC
No donor data found for current cycle
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC.
via HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC.
…control and protect against federal and state efforts to restrict it. H.R. 685 - SAVE Moms and Babies Act of 2025 All provisions This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (eit…
Q1 2025 total
all issues
Firms whose LDA filings mention this bill. One filing covers many bills — read as disclosed interest, not confirmed lobbying on this bill alone. Dollar amounts are each filer's total reported lobbying money for that reporting period across every issue in the filing. No public data breaks lobbying spending out by bill, so none of these figures is the amount spent on this bill.
Verify these filings on the Senate LDA database